• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Prilosec (omeprazole)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Prilosec (omeprazole)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Prilosec has been approved for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD). The recommended adult dose is 20 mg daily for up to four weeks in patients with symptomatic GERD.

    In addition to its new indication, Prilosec is also indicated for use in combination with the antibiotic Biaxin for the eradication of H. pylori infection associated with duodenal ulcers to reduce the risk of recurrence. H. Pylori is the bacterium now believed to cause approximately 90% of peptic ulcers. Prilosec is also indicated as first-line therapy for erosive esophagitis, for the maintenance of healed erosive esophagitis, for short-term treatment of active duodenal ulcer, and active benign gastric ulcer. It is also indicated for the treatment of certain pathological hypersecretory conditions.

    Side Effects

    Prilosec is generally well tolerated; side effects, which are usually transient and mild, include headache, diarrhea, abdominal pain and nausea.

    Additional Information

    Although many people experience heartburn from time to time, patients who get heartburn more than two to three times a week may have a more serious condition called GERD, an acid-related disorder affecting approximately 19 million Americans. GERD results when the lower esophageal sphincter, the muscle between the stomach and the esophagus, or food tube, relaxes allowing harsh stomach acid to splash back into the esophagus. GERD is a potentially serious medical condition, which can lead to significant complications, including ulcers, narrowing of the esophagus, and precancerous changes within the lining of the esophagus.

    Because heartburn is the most common symptom of GERD, the disease is often misunderstood and underestimated by patients and doctors. Prilosec significantly reduces acid directly at the final site of acid production, the acid pumps in the cells of the stomach.

    Approval Date: 1996-12-01
    Company Name: Astra Merck
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing